title: [Effect of postoperative transcatheter arterial chemoembolization on hepatocellular carcinoma patients with residual tumor].
abstract: OBJECTIVE
  To evaluate the effect of postoperative adjuvant transcatheter arterial chemoembolization (TACE) on hepatocellular carcinoma (HCC) patients with residual tumor.
  
  
  METHODS
  The patients were classified into intervention group (with adjuvant TACE) and control group (without adjuvant TACE) who were further stratified to those with high risk (patients with single tumor > 5 cm in diameter, or with multiple tumors, invasion to blood vessels), and low risk factors. Univariate analysis and Cox model were used to analyse prognostic factors.
  
  
  RESULTS
  In low risk patients with residual tumor, the 1-, 2-, 3-, 4-year survival rate was 97.2%, 78.0%, 66.5% and 66.5% in the intervention group, and 91.2%, 81.4%, 70.3% and 54.4% in the control group, respectively. There was no statistical difference between the two groups in survival (log-rank P = 0.7667). Comparing with the control group, the 1-, 2-, 3-, 4-year survival rate was 89.5%, 73.4%, 59.2% and 53.8% in the intervention group, and 70.5%, 61.9%, 46.8% and 46.8% in the control group, respectively. Postoperative adjuvant TACE significantly prolonged the survival in high risk patients with residual tumor (P = 0.0029). Cox model revealed that the benefit of adjuvant TACE was significantly increased by the high risk factors in HCC patients with residual tumor.
  
  
  CONCLUSIONS
  The beneficial effect of postoperative TACE was only observed in high risk patients with residual tumor but not in the low risk patients with residual tumor.
authors.affiliation: Liver Cancer Intitute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Zheng-gang
authors.initials: ZG
authors.lastname: Ren
authors.forename: Zhi-ying
authors.initials: ZY
authors.lastname: Lin
authors.forename: Jing-lin
authors.initials: JL
authors.lastname: Xia
authors.forename: Bo-heng
authors.initials: BH
authors.lastname: Zhang
authors.forename: Sheng-long
authors.initials: SL
authors.lastname: Ye
authors.forename: Shi-yao
authors.initials: SY
authors.lastname: Chen
authors.forename: Yu-hong
authors.initials: YH
authors.lastname: Gan
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Wu
authors.forename: Yi
authors.initials: Y
authors.lastname: Chen
authors.forename: Ning-ling
authors.initials: NL
authors.lastname: Ge
authors.forename: Zhi-quan
authors.initials: ZQ
authors.lastname: Wu
authors.forename: Zeng-chen
authors.initials: ZC
authors.lastname: Ma
authors.forename: Xin-da
authors.initials: XD
authors.lastname: Zhou
authors.forename: Jia
authors.initials: J
authors.lastname: Fan
authors.forename: Lun-xiu
authors.initials: LX
authors.lastname: Qin
authors.forename: Qing-hai
authors.initials: QH
authors.lastname: Ye
authors.forename: Hui-chuan
authors.initials: HC
authors.lastname: Sun
authors.forename: Jian
authors.initials: J
authors.lastname: Zhou
authors.forename: Zhao-you
authors.initials: ZY
authors.lastname: Tang
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D015996:Survival Rate